Serratus Plane Block After Minimally Invasive Mitral Valve Repair

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05648266

Enrollment

Registered

2022-12-13

Start date

2022-04-01

Completion date

2024-07-01

Last updated

2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimal Invasive Cardiac Surgery, Minimal Invasive Cardiac Surgery Mitral Valve Surgery, Serratus Anterior Plane Block

Brief summary

Patients undergoing minimally invasive mitral valve reconstruction via small thoracotomy are randomized into two groups. The intervention group receives serratus anterior plane block after minimally invasive mitral-valve reconstruction, following 48h infusion with ropivacaine 2% continually. The control group receives a placebo pump without infusion. Primary endpoints are perceived pain using a numeric pain rating scale and opioid consumption during the hospital stay.

Interventions

DRUGContinous SAPB (Ropivacain)

postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h

OTHERinstitutional standard of care pain medication protocol

institutional standard of care pain medication protocol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

-Planned minimal invasive mitral valve repair via right anterior thoracotomy

Exclusion criteria

* Pregenancy * Opioid abuse * Historyof chronic pain * Allergy to local anaesthetics (in this case ropivacain) * Patients who simultaneously participate in another interventional clinical trial, unless the Principal Investigators of the clinical trials give consent by mutual agreement Soft tissue infection in the area of the procedure

Design outcomes

Primary

Measure	Time frame	Description
Difference of Numeric Rating Scale after MIC-MKR	within 12, 24 and 48 hours after surgery	Numeric Rating Scale (0-10, 0=smallest value, 10=greatest value)

Secondary

Measure	Time frame	Description
Difference of opioid consumption after MIC-MVR	within 12, 24 and 48 hours after surgery	daily, cumulative dose of opioid analgetic medication after MIC-MKR

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026